GLP-1 Receptor Agonists and Sleep Apnea

A review published in JAMA Otolaryngology, Head and Neck Surgery on 3 September 2026 asks a deceptively simple question: what does the current evidence actually support when it comes to glucagon-like peptide-1 receptor agonists and obstructive sleep apnea (OSA)?^[1] The short answer is that one agent, tirzepatide, holds a formal approval for moderate-to-severe OSA in adults with obesity, backed by two randomised trials. The broader GLP-1 class sits in a murkier place, with meaningful AHI reductions in smaller studies but no approval pathway in most jurisdictions.

What SURMOUNT-OSA established

The bedrock of the field is SURMOUNT-OSA, the two-cohort Phase 3 randomised trial led by Atul Malhotra and Ronald Grunstein, published in the New England Journal of Medicine in June 2024^[2]. Tirzepatide is a dual GIP and GLP-1 receptor agonist, not a selective GLP-1 agent, but it is the most studied compound in this space and the one with the clearest regulatory standing.

The trial enrolled 469 adults with moderate-to-severe OSA (baseline AHI of 51.5 or 49.5 events per hour, depending on cohort) and obesity. Trial 1 recruited participants who were unwilling or unable to use positive airway pressure (PAP) therapy. Trial 2 recruited participants already established on PAP who agreed to continue it throughout the study.

Primary endpoint was the change in AHI from baseline to week 52. In Trial 1, tirzepatide produced a reduction of 25.3 events per hour versus 5.3 on placebo, a treatment difference of 20.0 events per hour (P less than 0.001), representing a 50.7% relative reduction. In Trial 2 the figures were 29.3 versus 5.5 events per hour, a treatment difference of 23.8 events per hour (P less than 0.001), representing a 58.7% relative reduction^[2]. Both cohorts also achieved clinically meaningful weight loss: 17.7% in Trial 1 and 19.6% in Trial 2, versus roughly 2% on placebo.

Secondary outcomes that broaden the picture

A secondary outcomes analysis published in Nature Medicine in January 2026 looked at cardiometabolic markers across both trials^[3]. Systolic blood pressure fell 7.9 mmHg more than placebo in Trial 1. High-sensitivity C-reactive protein dropped 28.9% more than placebo in Trial 1 and 45.1% more in Trial 2. Triglycerides fell by roughly 31 to 35% and HOMA-IR (a measure of insulin resistance) by approximately 48 to 55%, compared with placebo across both trials. The investigators interpreted the pattern as suggesting that treating OSA and obesity together produces cardiometabolic benefits that go beyond AHI alone.

How GLP-1 agonists are thought to work in OSA

A 2026 translational review in the International Journal of Molecular Sciences examined the proposed mechanisms^[4]. The most established pathway is mechanical: weight loss reduces adipose tissue deposited around the upper airway, lowering the collapsibility of the pharyngeal airspace and the AHI directly.

Beyond weight loss, the review ranks proposed mechanisms by evidence strength. Reductions in visceral adiposity, suppression of pro-inflammatory mediators such as TNF-alpha and IL-6, and improved insulin sensitivity are considered plausible but not yet confirmed as independent contributors. Direct effects on respiratory control and upper-airway neuromuscular tone are listed as hypothetical, lacking direct human evidence.

The review also notes that OSA and incretin biology interact in both directions. Intermittent hypoxia disrupts GLP-1 secretion from the gut, meaning the disease itself impairs the hormonal system these drugs target. Whether that feedback loop affects treatment response is not yet answered by clinical data.

What the selective GLP-1 agents contribute

Tirzepatide's dual mechanism makes it difficult to generalise its OSA results to selective GLP-1 receptor agonists such as semaglutide or liraglutide. The SCALE Sleep Apnea trial evaluated liraglutide in adults with OSA and obesity, and found statistically significant AHI reductions, but those reductions were smaller in absolute terms than those seen in SURMOUNT-OSA. No OSA-specific Phase 3 data exist for semaglutide. The translational review found no head-to-head comparisons between selective GLP-1 receptor agonists and tirzepatide in OSA populations.

The field therefore rests on one large randomised trial (SURMOUNT-OSA) and smaller studies in adjacent agents. That is a meaningful evidence base, but it does not support broad claims about the GLP-1 class as a class for OSA.

Where the regulatory landscape sits

The FDA approved Zepbound (tirzepatide) for moderate-to-severe OSA in adults with obesity in December 2024, the first US approval of any medication specifically for that indication. The label covers use alongside a reduced-calorie diet and increased physical activity, with or without concurrent PAP therapy.

In the EU, the EMA assessed Mounjaro (tirzepatide) for an OSA-specific indication and published its Q&A document (reference EMA/576853/2024) in December 2024. The EMA's position is that OSA is already included as a weight-related comorbidity within the existing Mounjaro weight-management authorisation, rather than as a stand-alone indication. There is no separate EMA label for OSA in the way the US Zepbound label creates one. The practical difference for prescribers is that the US label specifies OSA treatment explicitly, while EU prescribers are working within the weight-management authorisation. Country-level access and reimbursement conditions vary. See tirzepatide regulation by country for the current per-jurisdiction picture.

What this is not

GLP-1 and dual GIP/GLP-1 agonists are not a proven alternative to positive airway pressure therapy for most patients with symptomatic moderate-to-severe OSA. A forum of sleep medicine researchers published in the journal Sleep in June 2025 agreed that tirzepatide will likely be used alongside CPAP in most symptomatic cases rather than as a replacement, given that CPAP delivers immediate relief while the pharmacological effect on AHI unfolds over weeks to months.^[5]

The same group flagged several open questions: whether AHI improvements are durable beyond the 52-week SURMOUNT-OSA window; whether weight regain after stopping treatment reverses the OSA benefit; how patients without obesity respond; and what happens in obesity hypoventilation syndrome, a separate and more severe condition for which the SURMOUNT-OSA data do not apply.

The JAMA Otolaryngology review referenced at the top of this piece reflects the same caution that characterises the responsible end of this literature: the evidence for tirzepatide in OSA is real and comes from a well-powered trial, but the evidence for the GLP-1 class broadly is thinner, the mechanistic story is largely correlational, and several patient-centred outcome questions remain open.^[1]

Where this lands

For readers trying to understand what the research shows: tirzepatide has Phase 3 data and a US approval for OSA. Other GLP-1 agents have smaller, less definitive studies. The weight-loss mechanism is the most supported explanation, though additional pathways are being investigated. No prescriber should be discussing GLP-1 therapy for OSA without also discussing CPAP, weight history, and the specific regulatory status in the patient's country.

For readers following the regulatory picture: the US approval is explicit and tirzepatide-specific. The EU position incorporates OSA within existing weight-management authorisation rather than as a new indication. Outside those two jurisdictions, no national agency we track has issued an OSA-specific authorisation for any GLP-1 class agent. See the tirzepatide peptide page for the current regulatory status and the semaglutide peptide page for the parallel GLP-1 agonist picture.